PURPOSE: To characterize long-term MD Anderson Dysphagia Inventory (MDADI) results after primary intensity modulated radiation therapy (IMRT) for oropharyngeal carcinoma (OPC) among patients with "low-intermediate risk" OPC who would be eligible for current trials (eg, ECOG 3311, NRG HN002, CRUK PATHOS). METHODS AND MATERIALS: A retrospective pooled analysis combined data from 3 single-institution clinical trials for advanced-stage head and neck carcinoma. Inclusion criteria were clinical stage III/IV OPC (T1-2/N1-2b, T3/N0-2b) treated with definitive split-field IMRT and prospectively collected MDADI at baseline and at least 1 posttreatment interval available in trial databases. Patients were sampled to represent likely human papillomavirus (HPV)-associated disease (HPV+/p16+ or <10 pack-years if HPV/p16 unknown). The MDADI composite scores were collected at baseline and 6, 12, and 24 months after treatment. Pairwise tests were Bonferroni corrected for multiple comparisons. RESULTS: Forty-six patients were included. All received bilateral neck irradiation with a median dose of 70 Gy and systemic therapy (57% concurrent, 43% induction only). Overall the mean baseline MDADI composite score was 90.1, dropping to 74.6 at 6 months (P<.0001) and rising to 78.5 (P<.0001) and 83.1 (P=.002) by 12 and 24 months relative to baseline, respectively, representing a clinically meaningful drop in MDADI scores at 6 months that partially recovers by 24 months (6 vs 24 months, P=.05). Poor MDADI scores (composite <60) were reported in 4%, 11%, 15%, and 9% of patients at baseline and 6, 12, and 24 months, respectively. Fifteen percent of patients had a persistently depressed composite score by at least 20 points at the 24-month interval. CONCLUSION: "Low-intermediate risk" patients with OPC treated with laryngeal/esophageal inlet dose-optimized split-field IMRT are highly likely to report recovery of acceptable swallowing function in long-term follow-up. Only 15% report poor swallowing function and/or persistently depressed MDADI at 12 months or more after IMRT. These data serve as a benchmark future trial design and endpoint interpretation.
PURPOSE: To characterize long-term MD Anderson Dysphagia Inventory (MDADI) results after primary intensity modulated radiation therapy (IMRT) for oropharyngeal carcinoma (OPC) among patients with "low-intermediate risk" OPC who would be eligible for current trials (eg, ECOG 3311, NRG HN002, CRUK PATHOS). METHODS AND MATERIALS: A retrospective pooled analysis combined data from 3 single-institution clinical trials for advanced-stage head and neck carcinoma. Inclusion criteria were clinical stage III/IV OPC (T1-2/N1-2b, T3/N0-2b) treated with definitive split-field IMRT and prospectively collected MDADI at baseline and at least 1 posttreatment interval available in trial databases. Patients were sampled to represent likely human papillomavirus (HPV)-associated disease (HPV+/p16+ or <10 pack-years if HPV/p16 unknown). The MDADI composite scores were collected at baseline and 6, 12, and 24 months after treatment. Pairwise tests were Bonferroni corrected for multiple comparisons. RESULTS: Forty-six patients were included. All received bilateral neck irradiation with a median dose of 70 Gy and systemic therapy (57% concurrent, 43% induction only). Overall the mean baseline MDADI composite score was 90.1, dropping to 74.6 at 6 months (P<.0001) and rising to 78.5 (P<.0001) and 83.1 (P=.002) by 12 and 24 months relative to baseline, respectively, representing a clinically meaningful drop in MDADI scores at 6 months that partially recovers by 24 months (6 vs 24 months, P=.05). Poor MDADI scores (composite <60) were reported in 4%, 11%, 15%, and 9% of patients at baseline and 6, 12, and 24 months, respectively. Fifteen percent of patients had a persistently depressed composite score by at least 20 points at the 24-month interval. CONCLUSION: "Low-intermediate risk" patients with OPC treated with laryngeal/esophageal inlet dose-optimized split-field IMRT are highly likely to report recovery of acceptable swallowing function in long-term follow-up. Only 15% report poor swallowing function and/or persistently depressed MDADI at 12 months or more after IMRT. These data serve as a benchmark future trial design and endpoint interpretation.
Authors: Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: David I Rosenthal; Tito R Mendoza; Mark S Chambers; Joshua A Asper; Ibrahima Gning; Merrill S Kies; Randal S Weber; Jan S Lewin; Adam S Garden; K Kian Ang; Xin S Wang; Charles S Cleeland Journal: Head Neck Date: 2007-10 Impact factor: 3.147
Authors: Johannes A Langendijk; Patricia Doornaert; Irma M Verdonck-de Leeuw; Charles R Leemans; Neil K Aaronson; Ben J Slotman Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: Yogesh I More; Terance T Tsue; Douglas A Girod; John Harbison; Kevin J Sykes; Carson Williams; Yelizaveta Shnayder Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-01 Impact factor: 6.223
Authors: Klaudia U Hunter; Oliver E Lee; Teresa H Lyden; Marc J Haxer; Felix Y Feng; Mathew Schipper; Francis Worden; Mark E Prince; Scott A McLean; Gregory T Wolf; Carol R Bradford; Douglas B Chepeha; Avraham Eisbruch Journal: Head Neck Date: 2013-06-01 Impact factor: 3.147
Authors: Merrill S Kies; Floyd Christopher Holsinger; J Jack Lee; William N William; Bonnie S Glisson; Heather Y Lin; Jan S Lewin; Lawrence E Ginsberg; Katharine A Gillaspy; Erminia Massarelli; Lauren Byers; Scott M Lippman; Waun K Hong; Adel K El-Naggar; Adam S Garden; Vassiliki Papadimitrakopoulou Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: Puja Aggarwal; Jhankruti S Zaveri; Ryan P Goepfert; Qiuling Shi; Xianglin L Du; Michael Swartz; Stephen Y Lai; C David Fuller; Jan S Lewin; Linda B Piller; Katherine A Hutcheson Journal: Head Neck Date: 2019-08-23 Impact factor: 3.147
Authors: Alana Aylward; Sarah Abdelaziz; Jason P Hunt; Luke O Buchmann; Richard B Cannon; Shane Lloyd; Ying Hitchcock; Mia Hashibe; Marcus M Monroe Journal: Otolaryngol Head Neck Surg Date: 2019-06-11 Impact factor: 3.497
Authors: Ilya Likhterov; Meng Ru; Cindy Ganz; Mark L Urken; Raymond Chai; Devin Okay; Jerry Liu; Robert Stewart; Bruce Culliney; Daisy Palacios; Cathy L Lazarus Journal: Laryngoscope Date: 2018-10-16 Impact factor: 3.325
Authors: Kristina R Dahlstrom; Juhee Song; Peter F Thall; Clifton D Fuller; Katherine A Hutcheson; Faye M Johnson; G Brandon Gunn; Jack Phan; Steven J Frank; William H Morrison; Renata Ferrarotto; David I Rosenthal; Erich M Sturgis; Adam S Garden Journal: Cancer Date: 2020-12-11 Impact factor: 6.860
Authors: Jean-Jacques Stelmes; Vincent Gregoire; Vincent Vander Poorten; Wojciech Golusiñski; Mateusz Szewczyk; Terry Jones; Mohssen Ansarin; Martina A Broglie; Roland Giger; Jens Peter Klussmann; Mererid Evans; Jean Bourhis; C René Leemans; Giuseppe Spriano; Andreas Dietz; Keith Hunter; Frank Zimmermann; Ingeborg Tinhofer; Joanne M Patterson; Silvana Quaglini; Anne-Sophie Govaerts; Catherine Fortpied; Christian Simon Journal: Front Oncol Date: 2019-10-22 Impact factor: 6.244